An excellent example of how these aspects can be used for rational therapy design are shown in the phase 2 CAVALLI study, in which venetoclax, in combination with rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP), was especially effective in high-risk Bcl-2 Immunohistochemistry (IHC) positive subgroups of diffuse large B-cell lymphoma (DLBCL) patients [43]. Here, BCL2 is linked to diffuse large B-cell lymphoma.